Mitochondria-targeting therapeutic strategies for chronic kidney disease

Area of Science:

• Nephrology
• Mitochondrial Biology
• Pharmacology

Background:

• Chronic kidney disease (CKD) is a major global health concern with limited treatment options beyond renal replacement therapy.
• Mitochondrial dysfunction, involving oxidative stress, impaired biogenesis, fission, and mitophagy, is a key factor in CKD pathogenesis.
• Current CKD treatments do not halt disease progression to end-stage renal disease.

Purpose of the Study:

• To review recent evidence on mitochondria-targeting therapeutic strategies for CKD.
• To explore novel approaches, including naturally derived compounds and fusion proteins, for treating mitochondrial dysfunction in CKD.
• To assess the potential of these strategies to improve renal function.

Main Methods:

• Literature review of recent scientific evidence on mitochondria-targeting therapies for CKD.
• Categorization of mitochondrial dysfunction mechanisms implicated in CKD pathogenesis.
• Analysis of therapeutic strategies addressing oxidative stress, mitochondrial biogenesis, fission, and mitophagy.

Main Results:

• Mitochondrial dysfunction is a critical driver of CKD progression.
• Various mitochondria-targeting strategies, including natural compounds and fusion proteins, are being investigated.
• These novel approaches demonstrate potential in stabilizing or improving renal function in preclinical models.

Conclusions:

• Mitochondria-targeting therapies offer a promising avenue for novel CKD treatments.
• Further clinical studies are essential to establish the safety and efficacy of these strategies in humans.
• Addressing mitochondrial dysfunction could revolutionize CKD management and patient outcomes.